{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Showing 1 - 4 of 4 results
Status:
Investigational
Source:
NCT00358488: Phase 2 Interventional Completed Pulmonary Disease, Chronic Obstructive
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Milveterol (also known as GSK159797) was developed as a longer-acting beta2 adrenoceptor agonist for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Milveterol completed phase II clinical trials for asthmatic subjects. However further development of the drug was discontinued.
Status:
Investigational
Source:
NCT00358488: Phase 2 Interventional Completed Pulmonary Disease, Chronic Obstructive
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Milveterol (also known as GSK159797) was developed as a longer-acting beta2 adrenoceptor agonist for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Milveterol completed phase II clinical trials for asthmatic subjects. However further development of the drug was discontinued.
